Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study.

Lengsfeld S, Probst L, Emara Y, Werlen L, Vogt DR, Bathelt C, Baur F, Caviezel B, Vukajlovic T, Fischer M, Winzeler B

EBioMedicine4 Sept 2024Cited by 15 (Europe PMC)

PMID39232425PMCIDPMC11404067DOI10.1016/j.ebiom.2024.105284PepBankPUB-39232425

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy men, dulaglutide did not significantly change MGH-SFQ scores versus placebo.
In plain wordsIn healthy men, dulaglutide did not significantly change sexual desire scores versus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSexual desire questionnaire
Study
n = 24
Comparator
Placebo
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
Dose not stated · four weeksAs given in this study (human).
Measurements
Estimated difference in MGH-SFQ
0.58 score
dulaglutide versus placebo
Estimated difference CI lower
−0.83 score
95% CI
Estimated difference CI upper
2 score
95% CI
Source sentences
Summary
No change in the MGH-SFQ was observed after four weeks of dulaglutide versus placebo (estimated difference 0.58 [95% CI -0.83 to 2.00], p-value = 0.402).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks.
Report a problemFND-3923242501
02HumanRandomized controlled trialEfficacy outcome
In healthy men, total testosterone remained normal without significant differences between dulaglutide and placebo.
In plain wordsIn healthy men, testosterone remained normal and did not differ significantly between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTotal testosterone
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · four weeksAs given in this study (human).
Measurements
Estimated difference in total testosterone
0.9 nmol/l
dulaglutide versus placebo
Estimated difference CI lower
−1.5 nmol/l
95% CI
Estimated difference CI upper
3.3 nmol/l
95% CI
Source sentences
Summary
Hormones of the hypothalamic-pituitary-gonadal axis (estimated differences: total testosterone (nmol/l) 0.9 [95% CI -1.5 to 3.3], FSH (IU/l) -0.2 [95% CI -0.3 to 0.0] and LH (IU/l) -0.8 [95% CI -1.5 to 0.0]) as well as sperm parameters all remained in the normal range without significant differences…
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks.
Report a problemFND-3923242502
03HumanRandomized controlled trialEfficacy outcome
In healthy men, FSH remained normal without significant differences between dulaglutide and placebo.
In plain wordsIn healthy men, FSH remained normal and did not differ significantly between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeFSH
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · four weeksAs given in this study (human).
Measurements
Estimated difference in FSH
−0.2 IU/l
dulaglutide versus placebo
Estimated difference CI lower
−0.3 IU/l
95% CI
Estimated difference CI upper
0 IU/l
95% CI
Source sentences
Summary
Hormones of the hypothalamic-pituitary-gonadal axis (estimated differences: total testosterone (nmol/l) 0.9 [95% CI -1.5 to 3.3], FSH (IU/l) -0.2 [95% CI -0.3 to 0.0] and LH (IU/l) -0.8 [95% CI -1.5 to 0.0]) as well as sperm parameters all remained in the normal range without significant differences…
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks.
Report a problemFND-3923242503
04HumanRandomized controlled trialEfficacy outcome
In healthy men, LH remained normal without significant differences between dulaglutide and placebo.
In plain wordsIn healthy men, LH remained normal and did not differ significantly between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLH
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · four weeksAs given in this study (human).
Measurements
Estimated difference in LH
−0.8 IU/l
dulaglutide versus placebo
Estimated difference CI lower
−1.5 IU/l
95% CI
Estimated difference CI upper
0 IU/l
95% CI
Source sentences
Summary
Hormones of the hypothalamic-pituitary-gonadal axis (estimated differences: total testosterone (nmol/l) 0.9 [95% CI -1.5 to 3.3], FSH (IU/l) -0.2 [95% CI -0.3 to 0.0] and LH (IU/l) -0.8 [95% CI -1.5 to 0.0]) as well as sperm parameters all remained in the normal range without significant differences…
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks.
Report a problemFND-3923242504
05HumanRandomized controlled trialEfficacy outcome
In healthy men, sperm parameters remained normal without significant differences between dulaglutide and placebo.
In plain wordsIn healthy men, sperm measures remained normal and did not differ significantly between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSperm parameters
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · four weeksAs given in this study (human).
Source sentences
Summary
Hormones of the hypothalamic-pituitary-gonadal axis (estimated differences: total testosterone (nmol/l) 0.9 [95% CI -1.5 to 3.3], FSH (IU/l) -0.2 [95% CI -0.3 to 0.0] and LH (IU/l) -0.8 [95% CI -1.5 to 0.0]) as well as sperm parameters all remained in the normal range without significant differences…
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks.
Report a problemFND-3923242505

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In the healthy-men crossover trial of dulaglutide and placebo, no severe adverse events occurred.
In plain wordsIn the healthy-men trial of dulaglutide and placebo, no severe adverse events occurred.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSevere adverse events
Study
n = 24
Outcome group
Adverse events · Whole body
Source sentences
Summary
No severe adverse events occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover trial, healthy eugonadal men of normal weight, aged 18-50 years with active and satisfactory sex lifes were (1:1) randomly allocated to dulaglutide or placebo for four weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3923242506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.